Michaela Mattheus

19.7k citations

84 papers · 13.7k indexed · 5 hit papers · h-index 28

Impact in

Endocrinology, Diabetes and Metabolism top 0.02%
- Diabetes Treatment and Management
- Diabetes Management and Research
Nephrology top 0.2%
- Chronic Kidney Disease and Diabetes

Papers in

Endocrinology, Diabetes and Metabolism 78
- Diabetes Treatment and Management 76
- Diabetes Management and Research 26
Nephrology 12
- Chronic Kidney Disease and Diabetes 12

Co-authors: Bernard Zinman Christoph Wanner Silvio E. Inzucchi Uli C. Broedl Odd Erik Johansen John M. Lachin David Fitchett Hans J. Woerle
Journals: Diabetes Obesity and Metabolism (10 papers)Clinical Therapeutics (6 papers)European Heart Journal (5 papers)Diabetes (4 papers)Nephrology Dialysis Transplantation (4 papers)
Partner nations: Germany United States Canada

In The Last Decade

Michaela Mattheus

77 papers receiving 13.3k citations

Hit Papers

5 papers align trajectories log scale

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes 2019 · 394 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 JAMA
2017 Circulation
2017 The Lancet Diabetes & Endocrinology
2016 New England Journal of Medicine
2015 New England Journal of Medicine

Peers

Countries citing papers authored by Michaela Mattheus

Since Specialization

Citations

This map shows the geographic impact of Michaela Mattheus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michaela Mattheus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michaela Mattheus more than expected).

Fields of papers citing papers by Michaela Mattheus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michaela Mattheus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michaela Mattheus. The network helps show where Michaela Mattheus may publish in the future.

Co-authors

The 25 scholars most cited alongside Michaela Mattheus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michaela Mattheus Line = papers co-authored together Michaela Mattheus links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Early Changes in Estimated Glomerular Filtration Rate Post-Initiation of Empagliflozin in EMPEROR-Preserved European Journal of Heart Failure ·Luiz Felipe Manke, João Pedro Ferreira, Javed Butler, Bettina J. Kraus, Michaela Mattheus, Martina Brueckmann, Gerasimos Filippatos, Christoph Wanner, Stuart Pocock, Milton Packer, Stefan D. Anker, Faı̈ez Zannad	2024	10
2	An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium Therapeutic Innovation & Regulatory Science ·Zhizhi Zhou, Khairul Azmi, Віктор Петрович Молчанов, 智彦風間, Annett Keller, Michaela Mattheus, Ioannis Spyroglou, 正平関口, Susanne Korherr	2024	0
3	Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME Trial Kidney Medicine ·Samy Hadjadj, Mark E. Cooper, Dominik Steubl, İsmail Hakkı Alp Solak, Stefan Hantel, Michaela Mattheus, Christoph Wanner, Merlin C. Thomas	2023	1
4	Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial Diabetes Obesity and Metabolism ·Julio Rosenstock, Ahmed A. Kolkailah, Darren K. McGuire, Mark A. Espeland, Michaela Mattheus, Egon Pfarr, Søren S. Lund, Nikolaus Marx, (unknown)	2023	0
5	Cardiovascular outcomes trial data from EMPA‐REG OUTCOME , CAROLINA and CARMELINA : Assessment of a novel staging system for type 2 diabetes Diabetes Obesity and Metabolism ·M. Saeed Dar, Christoph Wanner, Nikolaus Marx, Anne Pernille Ofstad, Michaela Mattheus, Stefan Kaspers, Irina Dobrosmyslova	2023	1
6	Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials Stroke ·S. Alireza Zarabadi, Walter N. Kernan, Kevin N. Sheth, Anne Pernille Ofstad, Julio Rosenstock, Christoph Wanner, Bernard Zinman, Michaela Mattheus, Nikolaus Marx, Silvio E. Inzucchi	2023	6
7	Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome SHILAP Revista de lepidopterología ·Subodh Verma, A A Tyapkin, Deepak L. Bhatt, David Fitchett, Anne Pernille Ofstad, Christoph Wanner, Michaela Mattheus, Bernard Zinman, Patrick R. Lawler, Lawrence A. Leiter	2023	1
8	Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes Journal of Diabetes and its Complications ·Bernhard K. Krämer, Sibylle J. Hauske, Robert Ćhilton, Johannes F.E. Mann, Lars Gullestad, David Fitchett, Michaela Mattheus, Dominik Steubl, Christoph Wanner	2023	4
9	Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk Journal of Diabetes and its Complications ·Marc Quaghebeur, Bernard Zinman, Michaela Mattheus, Anne Pernille Ofstad, Dominik Steubl, Christoph Wanner, Silvio E. Inzucchi	2023	3
10	Kidney and Heart Failure Events are Bidirectionally Associated in Patients with Type 2 Diabetes and Cardiovascular Disease ESC Heart Failure ·Abhinav Sharma, Silvio E. Inzucchi, Jeffrey M. Testani, Anne Pernille Ofstad, David Fitchett, Michaela Mattheus, Subodh Verma, Faı̈ez Zannad, Christoph Wanner, Bettina J. Kraus	2023	9
11	Time to Cardiovascular Benefits of Empagliflozin: A Post Hoc Observation from the EMPA-REG OUTCOME Trial ESC Heart Failure ·Subodh Verma, Lawrence A. Leiter, Bernard Zinman, Abhinav Sharma, Michaela Mattheus, David Fitchett, Jyothis T. George, Anne Pernille Ofstad, Mikhail Kosiborod, Christoph Wanner, Silvio E. Inzucchi	2021	12
12	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes EClinicalMedicine ·Piero Ruggenenti, Bettina J. Kraus, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka‐Weber, Christoph Wanner	2021	10
13	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease Circulation ·Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, David Fitchett, Michaela Mattheus, Jyothis T. George, Hans J. Woerle, Uli C. Broedl, Maximilian von Eynatten, Bernard Zinman Hit paper breakdown →	2017	340
14	EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK Journal of the American College of Cardiology ·David Fitchett, Silvio E. Inzucchi, John M. Lachin, Christoph Wanner, Michaela Mattheus, Odd Erik Johansen, Hans‐Juergen Woerle, Uli C. Broedl, Bernard Zinman	2016	0
15	Assessing Pharmacokinetic Interactions Between the Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin and Hydrochlorothiazide or Torasemide in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Crossover Study Clinical Therapeutics ·Tim Heise, Michaela Mattheus, Hans J. Woerle, Uli C. Broedl, Sreeraj Macha	2015	21
16	Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial SHILAP Revista de lepidopterología ·Dingliang Zhu, Harold Bays, Jennifer L. Kuijer, Michaela Mattheus, Setelbanat Mohamed, Luís M. Ruilope	2013	7
17	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers Clinical Therapeutics ·Christian Friedrich, Nidyan Sumardani, Peter W. Rose, Michaela Mattheus, Sabine Pinnetti, Hans J. Woerle	2013	55
18	Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers International Journal of Clinical Pharmacology and Therapeutics ·Sreeraj Macha, 赵伟康, Michaela Mattheus, Leo Seman, Uli C. Broedl, Hans J. Woerle	2012	30
19	Efficacy and Tolerability of Initial Therapy With Single-Pill Combination Telmisartan/Hydrochlorothiazide 80/25 mg in Patients With Grade 2 or 3 Hypertension: A Multinational, Randomized, Double-Blind, Active-Controlled Trial Clinical Therapeutics ·Dingliang Zhu, Harold Bays, Pingjin Gao, Michaela Mattheus, Setelbanat Mohamed, Luís M. Ruilope	2012	13
20	Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers Advances in Therapy ·Íris Mist Magnúsdóttir, Sreeraj Macha, Michaela Mattheus, Sabine Pinnetti, Hans J. Woerle	2012	51

About Michaela Mattheus

Michaela Mattheus is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology, Surgery, Cardiology and Cardiovascular Medicine and Molecular Biology, having authored 84 papers that have together received 13.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (76 papers), Pancreatic function and diabetes (37 papers), Diabetes Management and Research (26 papers), Metabolism, Diabetes, and Cancer (21 papers), Chronic Kidney Disease and Diabetes (12 papers), Cardiovascular Function and Risk Factors (8 papers), Neuroendocrine Tumor Research Advances (5 papers) and Blood Pressure and Hypertension Studies (5 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (11.5k citations), Nephrology (1.8k citations), Cardiology and Cardiovascular Medicine (2.9k citations), Surgery (4.9k citations) and Pharmacology (1.3k citations). Michaela Mattheus has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Bernard Zinman, Christoph Wanner, Silvio E. Inzucchi, Uli C. Broedl, Odd Erik Johansen, John M. Lachin, David Fitchett, Hans J. Woerle, Stefan Hantel and Erich Bluhmki. Their work appears in journals such as Diabetes Obesity and Metabolism, Clinical Therapeutics, European Heart Journal, Diabetes and Nephrology Dialysis Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact